» Articles » PMID: 27010093

A Case of Recurrent Optic Neuritis Associated with Cerebral and Spinal Cord Lesions and Autoantibodies Against Myelin Oligodendrocyte Glycoprotein Relapsed After Fingolimod Therapy

Overview
Specialty Neurology
Date 2016 Mar 25
PMID 27010093
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

A previously healthy 16-year-old girl developed sudden eye pain and visual loss in her right eye. On day 7 from onset her right visual acuity had decreased to light perception, and she underwent 5 courses of intravenous methylprednisolone therapy (IVMP, 1 g/day for 3 consecutive days per week). Her eye pain and her visual acuity had improved immediately. Eleven months later, follow-up MRI revealed three T2-hyperintense plaques involving subcortical white matter in the left occipital lobe, right frontal lobe, right thalamus, and thoracic spinal cord. We suspected the diagnosis as multiple sclerosis and treated with fingolimod. She developed recurrent optic neuritis (ON) on day 19 from fingolimod therapy, and we stopped fingolimod. For two years from onset she was admitted five times due to recurrences of ON and appearance of white matter lesion and myelitis. At 22 months, anti-myelin oligodendrocyte glycoprotein (MOG) antibodies revealed to be positive in her sera from the onset to the present. Our case report suggests that fingolimod might not be effective in anti-MOG antibody-related disorders together with anti-aquaporin-4 (AQP4) antibody-positive group.

Citing Articles

Dimethyl Fumarate Was Ineffective but Not Harmful for a Patient with Myelin Oligodendrocyte Glycoprotein Antibody Disease.

Warabi Y, Takahashi T, Isozaki E Cureus. 2019; 11(10):e6040.

PMID: 31824807 PMC: 6886657. DOI: 10.7759/cureus.6040.


[MOG encephalomyelitis: international recommendations on diagnosis and antibody testing].

Jarius S, Paul F, Aktas O, Asgari N, Dale R, De Seze J Nervenarzt. 2018; 89(12):1388-1399.

PMID: 30264269 DOI: 10.1007/s00115-018-0607-0.


CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications.

Kaneko K, Sato D, Nakashima I, Ogawa R, Akaishi T, Takai Y J Neurol Neurosurg Psychiatry. 2018; 89(9):927-936.

PMID: 29875186 PMC: 6109242. DOI: 10.1136/jnnp-2018-317969.


MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.

Jarius S, Paul F, Aktas O, Asgari N, Dale R, De Seze J J Neuroinflammation. 2018; 15(1):134.

PMID: 29724224 PMC: 5932838. DOI: 10.1186/s12974-018-1144-2.